Last reviewed · How we verify
NCT06637345: MESORTIBO
Identification of Prognostic and Predictive Biomarkers of Toxicity in Patients With Malignant Pleural Mesothelioma and Treated With High Doses of Radiotherapy (MESORTIBO)
trial in Pleural Mesothelioma Malignant in 52 participants. Currently enrolling.
15 March 2027
Quick facts
| Lead sponsor | Centro di Riferimento Oncologico - Aviano |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 52 |
| Start date | 15 March 2024 |
| Primary completion | 15 March 2027 |
| Estimated completion | 15 March 2027 |
| Sites | 1 location across Italy |
Conditions studied
- Pleural Mesothelioma Malignant — all drugs for Pleural Mesothelioma Malignant →
Sponsor
Centro di Riferimento Oncologico - Aviano
Who can join
18 and older, any sex, with Pleural Mesothelioma Malignant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Malignant pleural mesothelioma (MPM) is a tumour that originates from the pleural layers (visceral and parietal) that envelop the lungs and the inner wall of the thoracic cage. In other tumour contexts, numerous studies have demonstrated a synergistic effect between RT and Immune Checkpoint Inhibitors (ICIs), mainly due to immunogenic effects attributed to high doses of RT and ICIs-mediated activation of anti-tumour T lymphocytes. Both treatments, RT and immunotherapy, have demonstrated a survival advantage in MPM, but are associated with non-negligible pulmonary toxicity. Therefore, the combination of these 2 therapeutic approaches requires a careful assessment of risk factors for the occurrence of toxicity. The identification of circulating biomarkers capable of predicting the onset of severe toxicity induced by radical radiation treatment is an important clinical need in MPM. This study aims to monitor circulating biomarkers, such as molecules involved in inflammation and oxidative stress and cellular effectors modulated by radiation treatment and potentially associated with the development of toxicity and/or markers of an immunogenic effect of radiotherapy in the peripheral blood of subjects with malignant pleural mesothelioma for treatment with radical hemithoracic radiotherapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Radical hemithorax radiotherapy induces an increase in circulating PD-1<sup>+</sup> T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?
Revelant A, Gessoni F, Montico M, Dhibi R, et al · · 2025 · cited 2× · PMID 40236706 · DOI 10.3389/fimmu.2025.1534766
Verify or expand the search:
- PubMed search for NCT06637345
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centro di Riferimento Oncologico - Aviano trials
Trials by the same sponsor.
- NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting
- NCT07344363 — Prostate Cancer REsearch Using Cross-validation of Innovative Sampling, Integrating LC-MS/MS for Optimized Therapeutic D · recruiting
- NCT07433777 — Reference Intervals With Indirect Methods in Italy · recruiting
- NCT07374731 — Identification of Biomarkers of Risk for Pre-neoplastic and Neoplastic Lesions for the Development of Gastric Cancer · recruiting
- NCT06738459 — Precision Retrospective Integrative Study for Metastatic Lymph Nodes in Breast Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06637345 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centro di Riferimento Oncologico - Aviano
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06637345.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing